Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes.

[1]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[2]  R. Heine,et al.  Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin‐treated patients with Type 2 diabetes mellitus , 2000, Diabetes/metabolism research and reviews.

[3]  A. Hamsten,et al.  Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). , 1998, Journal of the American College of Cardiology.

[4]  P. Barter,et al.  Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin. , 1998, Atherosclerosis.

[5]  P. Wilson,et al.  Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study. , 1998, Clinical chemistry.

[6]  J. Segrest,et al.  Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. , 1995, Journal of lipid research.

[7]  M. Laakso,et al.  Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. , 1995, Circulation.

[8]  G. Franceschini,et al.  Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[9]  G. Franceschini,et al.  Pravastatin effectively lowers LDL-cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern , 1994 .

[10]  H. Yamaguchi,et al.  Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. , 1994, Atherosclerosis.

[11]  R. Krauss,et al.  LDL Subclass Phenotypes and the Insulin Resistance Syndrome in Women , 1993, Circulation.

[12]  M. Austin,et al.  Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. , 1993, Atherosclerosis.

[13]  H. Ginsberg.  Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis , 1991, Diabetes Care.

[14]  W. Willett,et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.

[15]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[16]  E. Gong,et al.  Characterization of human high-density lipoproteins by gradient gel electrophoresis. , 1981, Biochimica et biophysica acta.

[17]  P. Wilson,et al.  Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. , 2001, Atherosclerosis.

[18]  K. Nakajima,et al.  Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients. , 2000, Journal of atherosclerosis and thrombosis.

[19]  T. Taniguchi,et al.  Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. , 1999, Diabetes care.

[20]  K. Nakajima,et al.  The possible role of remnant-like particles as a risk factor for sudden cardiac death , 1997, International Journal of Legal Medicine.

[21]  A. Hamsten,et al.  High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[22]  R. Krauss,et al.  Identification of multiple subclasses of plasma low density lipoproteins in normal humans. , 1982, Journal of lipid research.